PRCT Stock Risk & Deep Value Analysis
Procept Biorobotics Corp
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About PRCT Stock
We analyzed Procept Biorobotics Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PRCT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
How Risky Is PRCT Stock?
Overall Risk
Moderate
Financial Risk
Medium
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
Medium
What Are the Red Flags for PRCT?
- ⚠
Slower than expected adoption rates or competitive pressures in new markets
- ⚠
Potential regulatory hurdles or changes in reimbursement policies
- ⚠
Clinical trial setbacks or adverse safety profile concerns emerging
Unlock PRCT Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Procept Biorobotics Corp (PRCT) Do?
Market Cap
$1.74B
Sector
Healthcare
Industry
Medical Devices
Employees
756
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Visit Procept Biorobotics Corp WebsiteIs PRCT Stock Undervalued?
Unlock the full AI analysis for PRCT
Get the complete DVR score, risk analysis, and more
Does PRCT Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The proprietary nature of its Aquablation technology, backed by extensive patents and robust clinical data, creates a significant barrier to entry. As more urologists and hospitals adopt the system, training and integration costs increase switching costs for these institutions, enhancing durability.
Moat Erosion Risks
- •Emergence of a superior or equally effective, less invasive BPH treatment from competitors
- •Patent expiry or successful legal challenges to its intellectual property
- •Significant cost advantages developed by rivals with alternative therapies
PRCT Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive PRCT Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated early May 2026)
- •Continued acceleration of Aquablation procedure volumes and system placements (monthly/quarterly updates)
- •Expansion of CPT/reimbursement codes in key US regions or private payers
Medium-Term (6-18 months)
- •Announcement of new international market entries (e.g., major European or Asian countries)
- •Strategic partnerships to accelerate distribution or expand market reach
- •Updated long-term clinical data readouts further solidifying Aquablation efficacy
Long-Term (18+ months)
- •Aquablation therapy becoming the standard of care for BPH across major markets
- •Potential for platform expansion into adjacent urological indications or other soft tissue applications
- •Achieving sustainable profitability and significant free cash flow generation
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PRCT?
- ✓
Continued acceleration in quarterly Aquablation procedure volumes and system placements
- ✓
Positive updates on reimbursement expansion and international market penetration
- ✓
Improvement in gross margins and trajectory towards positive free cash flow
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PRCT (Procept Biorobotics Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
